Our clinical research activities include genetic, imaging (such as PET/MRI), electrophysiological and biomarker studies, as well as phase I-III clinical trials. Our basic research focuses on the generation of patient-derived stem cell models for ALS and FTD to study disease mechanisms. We also use these models to identify and validate molecular targets for new treatments.
MAGNET is an innovative clinical platform trial in which multiple treatments for ALS are investigated simultaneously.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.